Evidence map›Paper›PMID 41035535›Full record

ArticleOpen forum infectious diseases2025

Evaluating the Efficacy of Crushed Bictegravir/Emtricitabine/Tenofovir Alafenamide Administered via Tube.

Joshua Mercure, Kayla Bey, Eric Gillett, Jeffrey C Pearson, Suzanne M McCluskey, Alex E Rock

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Joshua MercureDepartment of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.ORCID https://orcid.org/0009-0007-4833-3073
Kayla BeyDepartment of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.ORCID https://orcid.org/0009-0009-3220-9785
Eric GillettDepartment of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.ORCID https://orcid.org/0000-0001-9528-8526
Jeffrey C PearsonDepartment of Pharmacy, Brigham and Women's Hospital, Boston, Massachusetts 02115, USA.ORCID https://orcid.org/0000-0002-5276-1050
Suzanne M McCluskeyDivision of Infectious Diseases, Massachusetts General Hospital, Boston, Massachusetts, USA.
Alex E RockDepartment of Pharmacy, Massachusetts General Hospital, Boston, Massachusetts 02114, USA.ORCID https://orcid.org/0000-0002-2067-4673

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Human immunodeficiency virus (HIV) viral suppression was evaluated after receipt of crushed or dissolved bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) administered via enteral tube during hospitalization. Eighty-nine percent of patients (17/19) were virally suppressed (<200 copies/mL) within 1 year of receiving B/F/TAF via tube, suggesting that administration via tube is a reasonable alternative to changing antiretroviral regimens.

Indexed as

bictegravircrushedenteral administrationHIVintegrase inhibitors

Identifiers

PMID41035535
PMCPMC12481155

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.